Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
2241-2251 of 2,251 trials

RSV Immunization Study: Nirsevimab for Infants

We are studying how the nirsevimab immunization affects infants' immune responses to RSV infections. This research aims to understand the role of age, weight, and maternal antibodies in developing immunity.

Healthy Infants1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Blood Cancer Treatment: Ciltacabtagene Autoleucel

We are studying the effects of a new infusion treatment for patients with blood cancers. The trial compares different ways of administering the treatment to see which is more effective and safe.

Newly Diagnosed Multiple MyelomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Open-Heart Surgery: Parasternal Block for Pain Relief

We are studying whether a special nerve block helps reduce pain and opioid use in patients recovering from open-heart surgery. This trial aims to improve recovery experiences for these patients.

Postoperative Pain Management>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal MedicineOtolaryngology

CIT-013 for Inflammatory Mediated Immune Diseases

We are studying how a new treatment, CIT-013, spreads in the body of patients with inflammatory mediated immune diseases. We also want to learn about its safety and how the body handles it.

Inflammatory Mediated Immune Diseases≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Chronic Constipation: Lecicarbon® Treatment Study

We are evaluating the safety and tolerability of long-term treatment with Lecicarbon® for people with chronic constipation. This study aims to understand how well patients can manage this treatment over time.

Chronic Constipation1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterology

Kidney Protection: Semaglutide and Finerenone in CKD

We are studying how semaglutide and finerenone may help protect the kidneys in people with chronic kidney disease. This includes patients with and without diabetes to explore their effects and mechanisms.

Chronic Kidney Disease6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNephrology

Influenza Vaccine Study: Seqirus H5N8

We are investigating how well the Seqirus H5N8 influenza vaccine works in adults who have been previously vaccinated and those who have never received an H5 vaccine. The study aims to assess immune responses and safety in both groups.

H5N1 Influenza Immunization≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInfectious Diseases

Influenza Vaccine Study for Adults

We are assessing a new mRNA-based vaccine to see how well it boosts the immune response and its safety in adults aged 18 and older. This study aims to improve protection against seasonal influenza.

Human Influenza6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

Metastatic Breast Cancer: Trastuzumab-Deruxtecan Study

We are studying how body weight influences the effects and side effects of trastuzumab-deruxtecan in patients with metastatic breast cancer. This research may help improve treatment strategies for different body types.

Metastatic Breast Cancer>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

CTNNB1 Syndrome: Gene Therapy Study for Kids

We are testing a new gene therapy given through an injection in the brain for children with CTNNB1 syndrome. The study aims to see if it is safe and if it may help improve their condition.

CTNNB1 Syndrome1-2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

COVID-19 Vaccine Study: BIMERVAX® LP.8.1

We are evaluating the safety and immune response of the BIMERVAX® LP.8.1 vaccine against COVID-19 variants. This study aims to understand how well it works in generating antibodies to fight the virus.

COVID-19≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious Diseases